Skip to main content
September 14, 2020
Physician assistants (PAs) may offer an effective way to ensure patients have access to quality mental health care despite the projected shortage of psychiatrists in the near future, according to a poster presented at Psych Congress 2020.
September 13, 2020
Psych Congress 2020 presenter Timothy Wilens, MD, discusses the ways in which early treatment can improve outcomes in patients with attention-deficit/hyperactivity disorder (ADHD). 
September 13, 2020
Psych Congress 2020 speaker Marc E. Agronin, MD, shares strategies that mental health clinicians can use to adjust psychopharmacologic treatment and dosages for geriatric patients.
September 12, 2020
Bernhard T. Baune, PhD, MD, head of the Department of Mental Health at the University of Münster, Germany, discusses the occurrence of cognitive deficits in patients with various psychiatric disorders.
September 12, 2020
Psych Congress 2020 cochair Vladimir Maletic, MD, MS, gives the latest updates on adult-onset attention deficit/hyperactivity disorder (ADHD).
September 12, 2020
Psych Congress 2020 presenter Timothy Wilens, MD, discusses the negative outcomes associated with attention-deficit/hyperactivity disorder (ADHD) that is left untreated.
September 11, 2020
In patients with comorbid chronic pain and substance use disorders, developing protocols for continuing opioid therapy are key for patient safety, W. Clay Jackson, MD, and Arwen Podesta, MD, DFASAM, DFAPA, ABIHM, told Psych Congress 2020 attendees.
September 11, 2020
Patients initiated on long-acting injectables for the treatment of schizophrenia had fewer hospitalizations and emergency department visits, compared with patients treated with oral antipsychotics, according to a poster presented at Psych Congress 2020. 
September 11, 2020
The metabolic profile of lumateperone 42 mg appears favorable, according to a post hoc analysis of a trio of studies involving patients with schizophrenia. Researchers shared their findings at Psych Congress 2020.
September 11, 2020
A 6-month extension of a published short-term trial showed continued improvement with SEP-363856 in patients with schizophrenia, researchers reported in a poster at Psych Congress 2020.
Back to Top